Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00033241
Status:
COMPLETED
Last Update Posted:
2018-01-10
First Post:
2002-04-09
Brief Title:
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
Sponsor:
OSI Pharmaceuticals
Organization:
Astellas Pharma Inc
Organization Data
Organization:
Astellas Pharma Inc
Class:
INDUSTRY
Study ID:
OSI-774-155
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
OSI Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Cancer Institute NCI | NIH |